TY - JOUR
T1 - Specialist perspectives on the imaging selection of large vessel occlusion in the late window
AU - Klein, Piers
AU - Huo, Xiaochuan
AU - Chen, Yimin
AU - Abdalkader, Mohamad
AU - Qiu, Zhongming
AU - Nagel, Simon
AU - Raymond, Jean
AU - Liu, Liping
AU - Siegler, James E.
AU - Strbian, Daniel
AU - Field, Thalia S.
AU - Yaghi, Shadi
AU - Qureshi, Muhammad M.
AU - Demeestere, Jelle
AU - Puetz, Volker
AU - Berberich, Anne
AU - Michel, Patrik
AU - Fischer, Urs
AU - Kaesmacher, Johannes
AU - Yamagami, Hiroshi
AU - Alemseged, Fana
AU - Tsivgoulis, Georgios
AU - Schonewille, Wouter J.
AU - Hu, Wei
AU - Liu, Xinfeng
AU - Li, Chuanhui
AU - Ji, Xunming
AU - Drumm, Brian
AU - Banerjee, Soma
AU - Sacco, Simona
AU - Sandset, Else C.
AU - Kristoffersen, Espen Saxhaug
AU - Slade, Peter
AU - Mikulik, Robert
AU - Romoli, Michele
AU - Diana, Francesco
AU - Krishnan, Kailash
AU - Dhillon, Permesh
AU - Lee, Jin Soo
AU - Kasper, Ekkehard
AU - Dasenbrock, Hormuzdiyar
AU - Ton, Mai Duy
AU - Masiliūnas, Rytis
AU - Arsovska, Anita Ante
AU - Marto, João Pedro
AU - Dmytriw, Adam A.
AU - Regenhardt, Robert W.
AU - Silva, Gisele Sampaio
AU - Siepmann, Timo
AU - Sun, Dapeng
AU - Sang, Hongfei
AU - Diestro, Jose Danilo
AU - Yang, Pengfei
AU - Mohammaden, Mahmoud H.
AU - Li, Fengli
AU - Masoud, Hesham E.
AU - Ma, Alice
AU - Raynald,
AU - Ganesh, Aravind
AU - Liu, Jianmin
AU - Meyer, Lukas
AU - Dippel, Diederik W.J.
AU - Thomalla, Götz
AU - Parsons, Mark
AU - Qureshi, Adnan I.
AU - Goyal, Mayank
AU - Yoo, Albert J.
AU - Lapergue, Bertrand
AU - Zaidat, Osama O.
AU - Chen, Hui Sheng
AU - Campbell, Bruce C.V.
AU - Jovin, Tudor G.
AU - Nogueira, Raul G.
AU - Miao, Zhongrong
AU - Saposnik, Gustavo
AU - Nguyen, Thanh N.
N1 - Funding Information:
S. Nagel: consultancy for Brainomix, speaker with Boehringer Ingelheim, Pfizer. T.S. Field: research grants from Bayer, consultancy for HLS Therapeutics, Roche. V. Puetz: lecturer Daiichi Sankyo. U. Fischer: research grants from Medtronic, Stryker, Rapid Medical, Penumbra, Phenox, Swiss Science Foundation, Swiss Heart Foundation; consultant Medtronic, Stryker, CSL Behring; advisory board for Alexion/Portola, Boehringer Ingelheim. H. Yamagami: research grants Bristol Myers Squibb, lecturer Bayer, Daiichi-Sankyo, Stryker, Bristol-Myers Squib; advisory Daiichi-Sankyo. S. Sacco: research grants Novartis and Uriach; advisor/speaker Abbott, Allergan-Abbvie, AstraZeneca, Lilly, Lundbeck, Novartis, Novo Nordisk, Pfizer, Teva. R. Mikulik: project IRENE COST Action-Implementation Research Network in Stroke Care Quality, INTER-EXCELLENCE INTER-COST program of Ministry of Education, Youth and Sports of Czech Republic. J.E. Siegler: speaker with AstraZeneca. R. Masiliūnas: IRENE COST Action-Implementation Research Network in Stroke Care Quality. J.P. Marto: consulting Amicus Therapeutics, Boehringer Ingelheim; Speaker Boehringer Ingelheim. J.D. Diestro: Honoraria from Medtronic, travel grant from Microvention. G. Thomalla: consultant Acandis, Alexion, Amarin, Bayer, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Portola, Stryker. M. Parsons: research Siemens, Canon, Apollo Medical Imaging. R.G. Nogueira: consulting Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, Synchron; advisory Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse, Perfuze; investments in Viz-AI, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic, Viseon. G. Saposnik: research grants, consulting from Roche; Editor-in-chief, World Stroke Academy. T.N. Nguyen: research support Medtronic, SVIN. P. Klein, X. Huo, Y. Chen, M. Abdalkader, Z. Qiu, J. Raymond, L. Liu, J.E. Siegler, D. Strbian, S. Yaghi, M.M. Qureshi, J. Demeestere, A. Berberich, P. Michel, J. Kaesmacher, F. Alemseged, G. Tsivgoulis, W.J. Schonewille, W. Hu, X. Liu, C. Li, X. Ji, B. Drumm, S. Banerjee, E.C. Sandset, E.S. Kristoffersen, P. Slade, M. Romoli, F. Diana, K. Krishnan, P. Dhillon, E. Kasper, H. Dasenbrock, M.D. Ton, A.A. Arsovska, A.A. Dmytriw, R.W. Regenhardt, G.S. Silva, T. Siepmann, D. Sun, H. Sang, P. Yang, M.H. Mohammaden, F. Li, H.E. Masoud, A. Ma, Raynald, A. Ganesh, J. Liu, L. Meyer, D.W.J. Dippel, A.I. Qureshi, M. Goyal, A.J. Yoo, B. Lapergue, O.O. Zaidat, H.-S. Chen, B.C.V. Campbell, T.G. Jovin, and Z. Miao declare that they have no competing interests.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
PY - 2023/9
Y1 - 2023/9
N2 - Background: The proper imaging modality for use in the selection of patients for endovascular thrombectomy (EVT) presenting in the late window remains controversial, despite current guidelines advocating the use of advanced imaging in this population. We sought to understand if clinicians with different specialty training differ in their approach to patient selection for EVT in the late time window. Methods: We conducted an international survey of stroke and neurointerventional clinicians between January and May 2022 with questions focusing on imaging and treatment decisions of large vessel occlusion (LVO) patients presenting in the late window. Interventional neurologists, interventional neuroradiologists, and endovascular neurosurgeons were defined as interventionists whereas all other specialties were defined as non-interventionists. The non-interventionist group was defined by all other specialties of the respondents: stroke neurologist, neuroradiologist, emergency medicine physician, trainee (fellows and residents) and others. Results: Of 3000 invited to participate, 1506 (1027 non-interventionists, 478 interventionists, 1 declined to specify) physicians completed the study. Interventionist respondents were more likely to proceed directly to EVT (39.5% vs. 19.5%; p < 0.0001) compared to non-interventionist respondents in patients with favorable ASPECTS (Alberta Stroke Program Early CT Score). Despite no difference in access to advanced imaging, interventionists were more likely to prefer CT/CTA alone (34.8% vs. 21.0%) and less likely to prefer CT/CTA/CTP (39.1% vs. 52.4%) for patient selection (p < 0.0001). When faced with uncertainty, non-interventionists were more likely to follow clinical guidelines (45.1% vs. 30.2%) while interventionists were more likely to follow their assessment of evidence (38.7% vs. 27.0%) (p < 0.0001). Conclusion: Interventionists were less likely to use advanced imaging techniques in selecting LVO patients presenting in the late window and more likely to base their decisions on their assessment of evidence rather than published guidelines. These results reflect gaps between interventionists and non-interventionists reliance on clinical guidelines, the limits of available evidence, and clinician belief in the utility of advanced imaging.
AB - Background: The proper imaging modality for use in the selection of patients for endovascular thrombectomy (EVT) presenting in the late window remains controversial, despite current guidelines advocating the use of advanced imaging in this population. We sought to understand if clinicians with different specialty training differ in their approach to patient selection for EVT in the late time window. Methods: We conducted an international survey of stroke and neurointerventional clinicians between January and May 2022 with questions focusing on imaging and treatment decisions of large vessel occlusion (LVO) patients presenting in the late window. Interventional neurologists, interventional neuroradiologists, and endovascular neurosurgeons were defined as interventionists whereas all other specialties were defined as non-interventionists. The non-interventionist group was defined by all other specialties of the respondents: stroke neurologist, neuroradiologist, emergency medicine physician, trainee (fellows and residents) and others. Results: Of 3000 invited to participate, 1506 (1027 non-interventionists, 478 interventionists, 1 declined to specify) physicians completed the study. Interventionist respondents were more likely to proceed directly to EVT (39.5% vs. 19.5%; p < 0.0001) compared to non-interventionist respondents in patients with favorable ASPECTS (Alberta Stroke Program Early CT Score). Despite no difference in access to advanced imaging, interventionists were more likely to prefer CT/CTA alone (34.8% vs. 21.0%) and less likely to prefer CT/CTA/CTP (39.1% vs. 52.4%) for patient selection (p < 0.0001). When faced with uncertainty, non-interventionists were more likely to follow clinical guidelines (45.1% vs. 30.2%) while interventionists were more likely to follow their assessment of evidence (38.7% vs. 27.0%) (p < 0.0001). Conclusion: Interventionists were less likely to use advanced imaging techniques in selecting LVO patients presenting in the late window and more likely to base their decisions on their assessment of evidence rather than published guidelines. These results reflect gaps between interventionists and non-interventionists reliance on clinical guidelines, the limits of available evidence, and clinician belief in the utility of advanced imaging.
KW - ASPECTS
KW - Endovascular thrombectomy
KW - Large vessel occlusion
KW - Late window
KW - Mechanical thrombectomy
UR - http://www.scopus.com/inward/record.url?scp=85151428275&partnerID=8YFLogxK
U2 - 10.1007/s00062-023-01284-0
DO - 10.1007/s00062-023-01284-0
M3 - Article
C2 - 37010551
AN - SCOPUS:85151428275
SN - 1869-1439
VL - 33
SP - 801
EP - 811
JO - Clinical Neuroradiology
JF - Clinical Neuroradiology
IS - 3
ER -